Future of ARD/ARS (2026)

The value proposition of Analysis Results Standards for sponsors and regulators, and the case for a lighter-weight ARD

2026
ARD
Published

September 13, 2026

Future of ARD/ARS

Value Proposition for Sponsors

  • Strong But Hard to Implement: The value proposition for sponsors adopting ARS (including Analysis Result Datasets) is much stronger than for regulators - but implementation remains a real challenge
  • Efficiency of TFL Generation: Standard analysis result datasets let sponsors generate TFLs efficiently from a shared intermediate form
  • Powerful Downstream Uses: When ARDs are curated well (especially cross-study, cross-indication), snapping a dashboard or a query chat on top can be very powerful
  • Metadata Curation is the Bottleneck: Doing this well requires deep metadata-curation expertise that many staff programmers do not have

Value Proposition for Regulators is Nebulous

  • FDA Isn’t Asking: Companies that have given ARDs to the FDA report that reviewers can generate different TFLs from them, but there’s no clear signal that FDA needs or wants this
  • “Nice, But For Them”: Reviewers often just want a static copy - the extra flexibility isn’t being requested
  • Uncertain ROI on the Regulator Side: Without demand, sponsors have less incentive to solve the hard implementation problems purely for regulator benefit

Complexity of the Standard

  • Convoluted UML: The ARS specification, as originally proposed, is a very complex UML diagram - even people familiar with ontologies find it hard to parse
  • Barrier to Effective Use: Understanding and effectively using ARS as currently specified is a real barrier to adoption

The Case for a “Light” ARS

  • Agent-Friendly Metadata: With the rise of AI agents, using an ARD with a smaller, lighter metadata layer as agent context can go a long way
  • Open Question: Is a lighter version of ARDs - one that agents can use effectively - enough for most purposes? That was the core discussion point

Overall Takeaway

Three main messages: the sponsor value proposition for ARS is strong but implementation is hard; the regulator value proposition is unclear because regulators aren’t asking for it; and the future of ARS may well be a “light” version that trades full specification complexity for something agents (and humans) can actually use.